TroFuse-027NCT06637423
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 26 versions: 23 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Primary completion date changed from estimate of Mar 14, 2029 to Sep 30, 2026
- Enrollment target: estimated 32 to confirmed 35
- Site details revised at 13 of 13 sites
- Minor Site details revised at 8 of 13 sites
- Notable Eligibility criteria expanded, about 5 words
- Secondary endpoints: details revised at 5 of 14 entries
- Study sites revised (13)
- Minor Study sites revised (13)v23
- Minor Site contacts updated at 1 of 13 sitesv22
- Notable Primary and study completion dates pushed to Mar 14, 2029
- Site details revised at 3 of 13 sites
- Minor Study sites revised (13)v20
- Minor Site contacts updated at 1 of 13 sitesv19
- Minor Site contacts updated at 1 of 13 sitesv17
- Minor Study sites: 12 to 13v16
- Minor Study sites: 11 to 12v14
- Minor Study sites: 10 to 11v13
- Minor Study sites: 9 to 10v12
- Minor Study sites: 8 to 9v11
- Minor Study sites: 6 to 8v10
- Minor Study sites: 5 to 6v9
- Notable Eligibility criteria expanded, about 7 words
- Interventions: Sacituzumab tirumotecan (Drug) to Rescue medication (Drug), Sacituzumab tirumotecan (Drug), Supportive care measures (Drug)
- Minor Study sites: 4 to 5v7
- Minor Study sites: 3 to 4
- Study completion date: Nov 30, 2026 to Jul 31, 2028
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Start date changed from estimate of Dec 26, 2024 to Dec 20, 2024
- Notable Eligibility criteria expanded, about 63 words
- Secondary endpoints: 5 to 14
- Minor Start date: Nov 27, 2024 to Dec 26, 2024v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Dose Limiting Toxicity (DLT)
Timeframe: Up to approximately 7 weeks
Number of Participants Experiencing an Adverse Event (AE)
Timeframe: Up to approximately 10 weeks
Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE)
Timeframe: Up to approximately 6 weeks
Secondary (14)
Area Under the Serum Concentration-Time Curve (AUC) of sacituzumab tirumotecan (sac-TMT) Antibody-Drug Conjugate (ADC)
Maximum Serum Concentration (Cmax) of sac-TMT ADC
Minimum Serum Concentration (Cmin) of sac-TMT ADC
Serum Apparent terminal half-life (t½) of sac-TMT ADC
Serum AUC of sac-TMT Total Antibody (TAb)
Show 9 moreShow less
Serum Cmax of sac-TMT Tab
Serum Cmin of sac-TMT Tab
Serum t½ of sac-TMT Tab
Plasma AUC of sac-TMT payload
Plasma Cmax of sac-TMT payload
Plasma Cmin of sac-TMT payload
Plasma t½ of sac-TMT payload
Complete Response Rate (CRR)
Duration of Complete Response (DCR)
Arms and interventions
Sacituzumab tirumotecanExperimental
Participants receive intravesical Sacituzumab Tirumotecan for 6 weeks
Drugs: Sacituzumab tirumotecan, Rescue medication, Supportive care measures
Sites
13 sites in 6 countries
United States 4, France 3, Canada 2, Spain 2, Netherlands 1, United Kingdom 1